CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) has launched a new clinical trial in the U.S. to test the effectiveness of its innovative CAR T-cell therapy CT041 for the treatment of advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ) in patients who have failed at least two prior lines of systemic therapies. This Phase 2 trial marks an exciting step forward in the fight against CLDN18.2 positive cancers and is expected to provide valuable insights into the potential of CAR T-cell therapy.
At CARsgen, we are dedicated to advancing the field of cancer immunotherapy so that we can offer new hope to those suffering from advanced forms of gastric cancer. Our chief medical officer, Dr. Raffaele Baffa, is proud to announce that our experimental therapy, CT041, has shown promising results in clinical trials and is well-tolerated with a manageable safety profile.
We are thrilled to continue our work towards our goal of developing effective CAR T-cell therapies that can offer relief to those affected by this devastating disease. We thank the patients, investigators, and our dedicated team at CARsgen for their commitment to this project. We look forward to providing updates on our clinical progress in the near future.
CAR T-cell therapy has taken a major leap forward with CT041, an autologous CAR T-cell product candidate targeting the protein CLDN18.2. CT041, with the potential to be the first-in-class globally, is actively being tested in clinical trials for the treatment of solid tumors, primarily focusing on gastric cancer/junction (GC/GEJ) and pancreatic cancer (PC).
With its Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA and PRIME eligibility from the EMA, CT041 is on the path to becoming a revolutionary treatment for advanced GC/GEJ and advanced gastric cancer.
Additionally, CT041 has received Orphan Drug designation from the U.S. FDA and Orphan Medicinal Product designation from the EMA, providing further support for its potential to change the way we treat these diseases.
About CARsgen Therapeutics Holdings Limited
CARsgen is a pioneering biopharmaceutical company that has dedicated itself to innovative CAR T-cell therapies. Their integrated cell therapy platform includes capabilities such as target discovery, antibody development, clinical trials, and commercial-scale manufacturing.
With a mission to make cancer curable, CARsgen has developed novel technologies and a product pipeline with global rights in order to address the major challenges of CAR T-cell therapies, such as improving safety, enhancing efficacy in treating solid tumors, and reducing treatment costs. CARsgen strives to become a global leader in cell therapies, providing cancer patients around the world with the hope of a cure.